Thyroid Cancer

A new orally active inverse agonist of estrogen-related receptor gamma (ERRү) called DN200434 shows promise with regard to the diagnosis and treatment of anaplastic thyroid cancer.

In late 2015, the American Thyroid Association (ATA) changed guideline recommendations trying to rein in overly aggressive treatment of thyroid cancers that are low risk, offering the choice of hemithyroidectomy as an alternative to total thyroidectomy in these patients. In participating hospitals, the rates of hemithyroidectomy went up.

Researchers examined several studies of patients with Graves' Disease to see the prevalence of thyroid cancer in this population.

Alan N. Peiris, MD spoke with ONCOLOGY about guidelines and strategies for treating patients who have had thyroid cancer. 

Researchers surveyed patients who underwent surgery for thyroid cancer and found a high number reported voice abnormalities post-operation.

Findings on the efficacy of the RET inhibitor BLU-667 in RET-altered medullary thyroid cancer and papillary thyroid cancer patients was presented at ASCO 2019.

Despite better detection, the incidence of pediatric thyroid cancer increased by 9.5% per year from 2006 to 2013 compared with 1.1% per year from 1973 to 2006.

Researchers found several risk factors for regional nodal recurrence in patients with papillary thyroid cancer, all of which can be easily evaluated in the clinical setting.

Vitamin D deficiency may be a negative prognostic indicator for papillary thyroid cancer, according to the results of a recent retrospective study.

A recent study in Surgery found that thyroid cancer survivors reported increased complications related to surgery and radioactive iodine ablation.

A recent study evaluated the impact of recommendations encouraging less aggressive lobectomy for patients with small papillary thyroid cancers.

Researchers evaluated the impact of dose interruption on survival for lenvatinib vs placebo in patients with progressive differentiated thyroid cancer.

A meta-analysis looked at the controversial link between decreased serum 25-hydroxyvitamin D levels and incidence of thyroid cancer.

According to the American Thyroid Association guidelines, noninvasive follicular thyroid neoplasm with papillary-like features is benign.

Researchers evaluated the incidence of physical, psychological, and lifestyle effects among patients with differentiated thyroid cancer.

A 45-year-old man presents with neck pain and a mass in the thyroid gland. What is your diagnosis?

Researchers conducted the first population-based study of an unselected MTC cohort compared with the general population.

Clinicians may be able to utilize this information as an effective preoperative tool to stratify risk and determine an initial surgical approach for patients with PTC.

The thyroid screening program put in place after the 2011 Fukushima Daiichi nuclear power station accident resulted in the diagnosis of a number of pediatric thyroid cancers.

The performance of three international guidelines in detecting thryoid cancer was compared based on their sensitivity and fine-needle aspiration rates.

The authors looked at whether rates of malignancy and false-negative fine-needle aspiration results are heightened in large thyroid nodules.

A study in Thyroid evaluated the safety and efficacy of concurrent intensity-modulated radiation therapy and doxorubicin in thyroid cancer.

Interim results are in from a study evaluating whether adding selumetinib to RAI improves complete response, irrespective of MAPK pathway alterations.

A new study in Cancer Management and Research found a correlation between the age of patients with papillary thyroid cancer and lymph node positivity.

LOXO-292, which selectively targets RET and has demonstrated preclinical activity against activating RET fusions/mutations, holds promise.

The eighth edition outperforms the seventh edition in predicting survival differences in patients with papillary thyroid cancer and follicular thyroid cancer.

The study confirmed a significant effect of male sex on PTC-specific patient survival in individuals with the most frequent oncogenic mutation.